About SH2 domain-containing protein 2A
SH2 domain-containing protein 2A (SH2D2A) is a protein
from Homo sapiens identified by UniProt accession
Q9NP31, 389 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | SH2 domain-containing protein 2A |
|---|
| UniProt accession | Q9NP31 |
|---|
| Gene | SH2D2A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 389 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (50)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- hypothyroidism · score 0.26
- breast adenocarcinoma · score 0.23
- lymphocyte count · score 0.23
- autoimmune disease · score 0.21
- thyroid disease · score 0.20
- myxedema · score 0.19
- autoimmune thyroid disease · score 0.18
- platelet crit · score 0.17
- calcium measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NP31-F1 | alphafold | PREDICTED | 61.17 | — |
Amino-acid sequence (389 residues)
MEFPLAQICP QGSHEAPIPT FSTFQITDMT RRSCQNLGYT AASPQAPEAA SNTGNAERAE EVPGEGSLFL QAETRAWFQK TQAHWLLQHG AAPAWFHGFI TRREAERLLE PKPQGCYLVR FSESAVTFVL TYRSRTCCRH FLLAQLRDGR HVVLGEDSAH ARLQDLLLHY TAHPLSPYGE TLTEPLARQT PEPAGLSLRT EESNFGSKSQ DPNPQYSPII KQGQAPVPMQ KEGAGEKEPS QLLRPKPPIP AKPQLPPEVY TIPVPRHRPA PRPKPSNPIY NEPDEPIAFY AMGRGSPGEA PSNIYVEVED EGLPATLGHP VLRKSWSRPV PGGQNTGGSQ LHSENSVIGQ GPPLPHQPPP AWRHTLPHNL SRQVLQDRGQ AWLPLGPPQ
Explore SH2 domain-containing protein 2A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets